Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $28M
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
- Six Flags names Mark Pauls as chief operating officer
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
